125 related articles for article (PubMed ID: 32060361)
21. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
Strebhardt K; Becker S; Matthess Y
Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
[TBL] [Abstract][Full Text] [Related]
22. Polo-like kinase 1 expression is suppressed by CCAAT/enhancer-binding protein α to mediate colon carcinoma cell differentiation and apoptosis.
Dasgupta N; Thakur BK; Ta A; Das S; Banik G; Das S
Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1777-1787. PubMed ID: 28341486
[TBL] [Abstract][Full Text] [Related]
23. Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
Kolberg M; Bruun J; Murumägi A; Mpindi JP; Bergsland CH; Høland M; Eilertsen IA; Danielsen SA; Kallioniemi O; Lothe RA
Mol Oncol; 2017 Sep; 11(9):1156-1171. PubMed ID: 28556483
[TBL] [Abstract][Full Text] [Related]
24. Long non‑coding RNA ZEB2‑AS1 affects cell proliferation and apoptosis via the miR‑122‑5p/PLK1 axis in acute myeloid leukemia.
Guan J; Liu P; Wang A; Wang B
Int J Mol Med; 2020 Oct; 46(4):1490-1500. PubMed ID: 32700753
[TBL] [Abstract][Full Text] [Related]
25. Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
Zhong H; Xin S; Zhao Y; Lu J; Li S; Gong J; Yang Z; Lin S
Mol Biosyst; 2010 Aug; 6(8):1463-8. PubMed ID: 20625580
[TBL] [Abstract][Full Text] [Related]
26. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
[TBL] [Abstract][Full Text] [Related]
29. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
30. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
Stehle A; Hugle M; Fulda S
Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
[TBL] [Abstract][Full Text] [Related]
31. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
32. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
33. Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.
Tao YF; Li ZH; Du WW; Xu LX; Ren JL; Li XL; Fang F; Xie Y; Li M; Qian GH; Li YH; Li YP; Li G; Wu Y; Feng X; Wang J; He WQ; Hu SY; Lu J; Pan J
Oncol Rep; 2017 Mar; 37(3):1419-1429. PubMed ID: 28184925
[TBL] [Abstract][Full Text] [Related]
34. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells.
Schmit TL; Zhong W; Setaluri V; Spiegelman VS; Ahmad N
J Invest Dermatol; 2009 Dec; 129(12):2843-53. PubMed ID: 19554017
[TBL] [Abstract][Full Text] [Related]
35. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
36. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer.
Shi W; Alajez NM; Bastianutto C; Hui AB; Mocanu JD; Ito E; Busson P; Lo KW; Ng R; Waldron J; O'Sullivan B; Liu FF
Int J Cancer; 2010 May; 126(9):2036-48. PubMed ID: 19739117
[TBL] [Abstract][Full Text] [Related]
37. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC.
Wang H; Tao Z; Feng M; Li X; Deng Z; Zhao G; Yin H; Pan T; Chen G; Feng Z; Li Y; Zhou Y
Biochem Biophys Res Commun; 2020 Dec; 533(3):368-375. PubMed ID: 32962858
[TBL] [Abstract][Full Text] [Related]
38. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
[TBL] [Abstract][Full Text] [Related]
39. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
40. BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
Chen E; Pei R
J Int Med Res; 2020 May; 48(5):300060520926093. PubMed ID: 32468878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]